NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License ...
The FINANCIAL — Allergan plc on August 20 announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s resubmission of its Supplemental Biologics License Application (sBLA) ...
The use of Botox (BTX-A) as a safe, reversible, and effective treatment for reducing muscle tone and improving gait in children with cerebral palsy. Children have barriers to care in the US despite ...
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport® (abobotulinumtoxinA) in Pediatric Lower ...
Background OnabotulinumtoxinA has demonstrated significant benefit in adult focal spasticity. This study reviews the injection patterns (i.e., muscle distribution, dosing) of onabotulinumtoxinA for ...
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity
Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its Supplemental Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results